Mutations in SEPN1 and ACTA1 disrupt muscle cells in CMD-RS. Genetic testing can confirm the diagnosis, guide treatment choices and find carriers for prenatal testing.
Inheritance shapes recurrence risk: dominant CMS carries a 50% transmission chance, recessive 25% when both parents carry it. EMG, RNS and gene testing are described.
Alpha-hydroxyisovalerate is a blood metabolite whose low levels are linked to axial spondyloarthritis and cancer; measurement and DNA analysis are outlined.
Cognitive decline, hearing loss and impaired limb sensation occur together in this rare disorder; ATP1A1, FITM2 and DNMT1 variants appear in the case studies.
Mutations in the MYO5B gene disrupt intestinal microvilli and cause severe newborn diarrhea. Clinical assessment, intestinal biopsy and carrier testing are covered.
Two mutated copies of a gene such as TTN, LMNA, MYH7 or BAG3 are needed for this rare familial form, and the gene involved shapes severity, age of onset and treatment.
Symptoms that match no defined disorder are labeled Not Otherwise Specified; DNA analysis may point to a cause, inform treatment choices and clarify risk for relatives.
Kidneys that cannot excrete enough acid lead to growth retardation, kidney stones and bone deformities; diagnosis combines lab tests, genetics and alkali therapy.